Details for Patent: 12,303,481
Which drugs does patent 12,303,481 protect, and when does it expire?
Patent 12,303,481 protects CREXONT and is included in one NDA.
This patent has seven patent family members in seven countries.
Summary for Patent: 12,303,481
| Title: | Levodopa dosing regimen |
| Abstract: | The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets. |
| Inventor(s): | Richard D'Souza, Hester Visser, Suneel Gupta |
| Assignee: | Amneal Pharmaceuticals LLC |
| Application Number: | US18/802,151 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,303,481 |
|
Patent Claim Types: see list of patent claims | Use; Device; Dosage form; |
Drugs Protected by US Patent 12,303,481
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | 12,303,481 | ⤷ Start Trial | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | 12,303,481 | ⤷ Start Trial | TREATMENT OF PARKINSON'S DISEASE | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | 12,303,481 | ⤷ Start Trial | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | 12,303,481 | ⤷ Start Trial | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-002 | Aug 7, 2024 | RX | Yes | No | 12,303,481 | ⤷ Start Trial | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-002 | Aug 7, 2024 | RX | Yes | No | 12,303,481 | ⤷ Start Trial | TREATMENT OF PARKINSON'S DISEASE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,303,481
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3196650 | ⤷ Start Trial | |||
| China | 116801869 | ⤷ Start Trial | |||
| Colombia | 2023009085 | ⤷ Start Trial | |||
| European Patent Office | 4267113 | ⤷ Start Trial | |||
| Japan | 2024501235 | ⤷ Start Trial | |||
| South Korea | 20230124622 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
